Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron isomaltoside with or without dopaminergic therapy in restless legs syndrome
2024-512117-40-00Phase 3Authorised
- Sponsor
- Medical University of Innsbruck
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferric derisomaltose in restless legs syndrome (RLS) (4 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Change in IRLS score. Planned start Oct 2024; status: authorised.
02
Drugs
ferric derisomaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2024-512117-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512117-40-00.